Product Images Norelgestromin And Ethinly Estradiol

This is information about a medication with the NDC code 69238-1521-1. The medication is called Norelgestromin and Ethinyl Estradiol Transdermal System. It provides 150,35 mcg per day. The text also possibly mentions instructions on preventing pregnancy. The rest of the text appears to be either scrambled or incomplete and does not provide any further details.*

This is a product description of Norelgestromin and Ethinyl Estradiol Transdermal System, a contraceptive product intended to prevent pregnancy. It contains 3.15 mg norelgestromin and 0.289 mg ethinyl estradiol per system and is intended for transdermal use only. The package includes 3 transdermal systems, which should be worn as prescribed for 7 days each. The product should be stored at 20° to 25°C and not stored unpouched. The package is not child-resistant and must be kept out of reach of children. It does not protect against HIV infections and other sexually transmitted diseases. The product is distributed by Amneal Pharmaceuticals LLC.*

This appears to be a table with some demographic information and statistics relating to blood clots in women. The table includes information on pregnancy status, postpartum status, and the incidence of blood clots in terms of the number of women affected out of 10,000 woman-years. It is unclear what the actual numbers in the table represent without further context.*

This is a list of studies that assess the risk of breast cancer associated with the use of combined oral contraceptives. The studies cited are NICHD Women's Contraceptive Study, French E3N cohort Study, Shanghai Women's Health Study, The Nurses' Health Study II, and Oxford Family Planning Association Study. Each study gives results for ever use and current use of contraceptives, and the table provides effect estimates (OR/RR), with confidence intervals.*